Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis
No Thumbnail Available
Date
2013-07
Authors
Korkmaz, Taner
Seber, Selçuk
Kefeli, Umut
Sarı, Enes
Öven, Bala Başak
Yıldırım, Emre
Yaşar, Nurgül
Balvan, Özlem
Şener, Nur Dinç
Yüksel, Sinemis
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Description
Keywords
Oncology, Platinum sensitive disease, Platinum refracter disease, Second-line chemotherapy, Small cell lung cancer, Phase-II, Topotecan, Chemotherapy, Etoposide, Cisplatin, Progress, Therapy, Trial, Care
Citation
Korkmaz, T. vd. (2013). ''Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis''. Clinical and Translational Oncology, 15(7), 535-540.